ACOR is short from $48.73. The stock was halted at $20.33, down $6.44. The stock was being crushed before the halt as patents on Ampyra are invalidated. ACOR came to fame on Ampyra, a drug that marginally helps MS patients’ walking.
We have a long history with shorting this stock.
Before the halt the stock had fallen into the target zone of $14 to $21. 20% of the full core position size is being held.
What To Do Now
If the stock opens lower or right around the close before the halt, depending upon your account size, consider taking profits on one-quarter to one-half of your position.